American Academy of Arts & Sciences
Peter Slavin, MD, serves as the President and CEO Elect at Cedars-Sinai as of July 2024 and holds the position of Operating Partner at Advent International since April 2022. Slavin has been a Board Member at Amwell and Point32Health since December 2016 and September 2022, respectively. Additionally, Slavin provides advisory services to Tredence Inc., Droplet Biosciences, Inc., Joyous, Florence, and Perry Health, all since early 2023. An Advisory Board Member at Arsenal Capital Partners since June 2015, Slavin possesses a strong educational background, including a Doctor of Medicine degree from Harvard Medical School and an MBA from Harvard Business School, along with a Bachelor of Arts in Biochemical Sciences from Harvard University.
This person is not in any offices
American Academy of Arts & Sciences
Since its founding in 1780, the American Academy has served the nation as a champion of scholarship, civil dialogue, and useful knowledge. As one of the nation’s oldest learned societies and independent policy research centers, the Academy convenes leaders from the academic, business, and government sectors to address critical challenges facing our global society. Through studies, publications, and programs on the Humanities, Arts, and Education; Science, Engineering, and Technology; Global Security and International Affairs; and American Institutions and the Public Good, the Academy provides authoritative and nonpartisan policy advice to decision-makers in government, academia, and the private sector. The Academy’s membership of 4,600 Fellows and 600 International Honorary Members includes many of the most accomplished scholars and practitioners worldwide. The Academy frequently sponsors meetings, lectures, panel discussions, and informal gatherings around the country. Topics are drawn from Academy projects and studies as well as the research and writings of Academy members. Academy publications include the journal Dædalus; a magazine, the Bulletin; and books, research papers, and other special reports.